Financial Performance - The company's revenue for Q1 2025 was CNY 291,475,651.27, representing a 2.35% increase compared to CNY 284,795,525.11 in the same period last year[4] - Net profit attributable to shareholders for Q1 2025 was CNY 32,531,877.20, up 12.27% from CNY 28,976,245.02 year-on-year[4] - Operating profit increased to ¥42,361,044.87, reflecting a growth of 11.43% from ¥37,983,244.96 in the previous period[18] - The total comprehensive income for the current period was ¥31,250,225.55, compared to ¥27,182,272.93 in the previous period, indicating growth[18] - The basic and diluted earnings per share were both ¥0.2059, an increase from ¥0.1834 in the previous period[18] Cash Flow and Investments - The net cash flow from operating activities increased by 36.89% to CNY 79,942,280.03, compared to CNY 58,399,019.66 in the previous year[4] - Cash flow from operating activities generated a net amount of ¥79,942,280.03, compared to ¥58,399,019.66 in the previous period, marking a significant increase[20] - The company reported a net cash outflow from investing activities of ¥323,196,773.08, compared to a smaller outflow of ¥25,303,495.08 in the previous period[20] - The company's cash and cash equivalents decreased to CNY 514,507,643.98 from CNY 767,321,351.31, representing a decline of approximately 32.9%[15] - The company’s cash and cash equivalents at the end of the period were ¥513,584,939.29, down from ¥1,578,132,841.44 at the end of the previous period[21] Assets and Liabilities - Total assets at the end of Q1 2025 were CNY 2,262,226,831.53, a 1.65% increase from CNY 2,225,440,397.53 at the end of the previous year[4] - The total assets of the company as of March 31, 2025, amounted to CNY 2,262,226,831.53, an increase from CNY 2,225,440,397.53 at the beginning of the period[15] - The company's total liabilities rose to CNY 351,010,403.58 from CNY 345,714,195.13, indicating an increase of approximately 1.0%[16] - The company's inventory decreased to CNY 70,861,668.62 from CNY 74,991,587.59, a decline of approximately 5.5%[15] - The company's non-current assets totaled CNY 791,568,709.65, down from CNY 820,293,209.09, indicating a decrease of about 3.5%[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 9,399, with no preferred shareholders[10] - The company reported a total of 2,722,719 shares in its repurchase account, accounting for 1.72% of the total share capital[12] Financial Challenges - Financial expenses for Q1 2025 increased by 78.91% to CNY -1,243,700, primarily due to a decrease in bank interest[9] - Other income decreased by 52.13% to CNY 660,800, mainly due to a reduction in government subsidies compared to the previous year[9] - The company experienced a 64.63% increase in asset impairment losses, totaling CNY -415,800, primarily due to a decrease in inventory write-down provisions[11] Accounting and Governance - The first quarter report has not been audited[22] - The new accounting standards will be implemented starting in 2025[22] - The board of directors meeting was held on April 24, 2025[23]
何氏眼科(301103) - 2025 Q1 - 季度财报